论文部分内容阅读
目的比较通心络胶囊联合阿托伐他汀与单用阿托伐他汀对冠心病患者血脂、炎症因子水平的影响。方法将温州医科大学附属第三医院2014年3月—2016年3月收治的172例冠心病患者采用随机数字法分为2组,每组86例。对照组给予阿托伐他汀,观察组在此基础上加用通心络胶囊。治疗前、后,检测患者血脂[(甘油三酯(TG)、胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)]和炎症因子(IL-4、IL-10和IL-18)水平,并统计治疗效果和不良反应情况。结果观察组总有效率为74.4%,显著高于对照组的51.1%(P<0.05)。治疗前,2组TG、TC、LDL-C、HDL-C水平比较差异无统计学意义(P>0.05)。治疗后,2组TG、TC、LDL-C、HDL-C水平显著改善(P<0.05),观察组TG、TC、LDL-C、HDL-C水平改善显著优于对照组(P<0.05)。治疗前,2组IL-4、IL-10、IL-18水平比较差异无统计学意义(P>0.05)。治疗后,2组IL-4、IL-10、IL-18水平显著改善(P<0.05),观察组IL-4、IL-10、IL-18水平改善显著优于对照组(P<0.05)。2组均未出现严重不良反应。结论相比于单用阿托伐他汀,通心络胶囊联合阿托伐他汀可有效改善冠心病患者血脂、炎症因子水平,治疗效果满意。
Objective To compare the effects of Tongxinluo capsule combined with atorvastatin and atorvastatin on blood lipids and inflammatory cytokines in patients with coronary heart disease. Methods The 172 patients with coronary heart disease admitted to the Third Affiliated Hospital of Wenzhou Medical University from March 2014 to March 2016 were divided into two groups (n = 86) by random number method. The control group was given atorvastatin, the observation group was added Tongxinluo capsule on the basis of this. The levels of serum lipids (TG, TC, HDL-C and HDL-C) and inflammatory cytokines (IL- 4, IL-10 and IL-18) were measured.Results The total effective rate in the observation group was 74.4%, which was significantly higher than that in the control group (51.1%, P <0.05) TG, TC, LDL-C and HDL-C had no significant difference (P> 0.05), after treatment, TG, TC, LDL-C and HDL- The levels of TG, TC, LDL-C and HDL-C in the two groups were significantly better than those in the control group (P <0.05) .There was no significant difference in the levels of IL-4, IL-10 and IL- > 0.05) .After treatment, the levels of IL-4, IL-10 and IL-18 in the two groups were significantly improved (P <0.05), and the levels of IL-4, IL-10 and IL-18 in the observation group were significantly better than those in the control group P <0.05) .There was no serious side effects in both groups.Conclusion Tongxinluo capsule combined with atorvastatin can effectively improve blood lipid and inflammatory cytokines in patients with coronary heart disease compared with atorvastatin alone, and the treatment effect is satisfactory.